Literature DB >> 25168668

A comprehensive Fabry-related pain questionnaire for adult patients.

Nurcan Üçeyler1, Barbara Magg2, Phillip Thomas3, Silke Wiedmann4, Peter Heuschmann5, Claudia Sommer2.   

Abstract

Pain may be the earliest symptom in Fabry disease and presents with a distinct phenotype including triggerable pain attacks, evoked pain, pain crises, and chronic pain. Current pain questionnaires do not reflect the special phenotype of Fabry disease-associated pain, which hampers its systematic evaluation as the basis of correct diagnosis and effective treatment. A questionnaire specifically designed to assess Fabry disease-associated pain is thus urgently needed. At the Würzburg Fabry Center for Interdisciplinary Therapy (FAZIT), Germany, we developed and validated the first face-to-face Fabry Pain Questionnaire (FPQ) for adult patients. The initial version of the FPQ was tested in a pilot study with 20 consecutive Fabry disease patients. The performance of the revised FPQ was assessed in a first (n=56) and second (n=20) validation phase in consecutive Fabry disease patients. For this, patients were interviewed at baseline and 2 weeks later. We determined the test-retest reliability and validity of the FPQ in comparison to data obtained with the Neuropathic Pain Symptom Inventory. The FPQ contains 15 questions on the 4 pain phenotypes of Fabry disease (pain attacks, pain crises, evoked pain, chronic pain) in childhood and adulthood, on pain development during life with and without enzyme replacement therapy, and on everyday life impairment due to pain. This first disease-specific questionnaire is a valuable tool for baseline and follow-up assessment of pain in Fabry disease patients and may guide treatment in this distinct pain phenotype.
Copyright © 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Evoked pain; Fabry Pain Questionnaire; Fabry disease; Neuropathic pain; Pain attacks; Pain crises

Mesh:

Year:  2014        PMID: 25168668     DOI: 10.1016/j.pain.2014.08.024

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

1.  Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.

Authors:  Christoph Wanner; Virginia Kimonis; Juan Politei; David G Warnock; Nurcan Üçeyler; Aline Frey; Peter Cornelisse; Derralyn Hughes
Journal:  Mol Genet Metab Rep       Date:  2022-03-26

Review 2.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.

Authors:  Michela Ranieri; Gloria Bedini; Eugenio Agostino Parati; Anna Bersano
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

3.  L-Acetylcarnitine causes analgesia in mice modeling Fabry disease by up-regulating type-2 metabotropic glutamate receptors.

Authors:  Francesco Formaggio; Roberto Rimondini; Cecilia Delprete; Leonardo Scalia; Emilio Merlo Pich; Rocco Liguori; Ferdinando Nicoletti; Marco Caprini
Journal:  Mol Pain       Date:  2022 Jan-Dec       Impact factor: 3.395

4.  Self-administered version of the Fabry-associated pain questionnaire for adult patients.

Authors:  Barbara Magg; Christoph Riegler; Silke Wiedmann; Peter Heuschmann; Claudia Sommer; Nurcan Üçeyler
Journal:  Orphanet J Rare Dis       Date:  2015-09-17       Impact factor: 4.123

5.  Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.

Authors:  Juan M Politei; Didier Bouhassira; Dominique P Germain; Cyril Goizet; Antonio Guerrero-Sola; Max J Hilz; Elspeth J Hutton; Amel Karaa; Rocco Liguori; Nurcan Üçeyler; Lonnie K Zeltzer; Alessandro Burlina
Journal:  CNS Neurosci Ther       Date:  2016-03-28       Impact factor: 5.243

6.  English version of the self-administered Fabry Pain Questionnaire for adult patients.

Authors:  Ana Jovanovic; Philipp Klassen; Peter Heuschmann; Claudia Sommer; Mark Roberts; Nurcan Üçeyler
Journal:  Orphanet J Rare Dis       Date:  2020-10-20       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.